EW · Categories · Upgrades
EW - Analyst upgrades
Edwards Lifesciences Corporation (EW) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for EW
- Edwards Lifesciences upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Edwards Lifesciences from Market Perform to Outperform and set a new price target of $101.00
- Edwards Lifesciences upgraded by Wolfe Research with a new price targetWolfe Research upgraded Edwards Lifesciences from Peer Perform to Outperform and set a new price target of $92.00
- Edwards Lifesciences upgraded by TD Cowen with a new price targetTD Cowen upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $97.00
- Edwards Lifesciences upgraded by Analyst with a new price targetAnalyst upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $100.00
- Edwards Lifesciences upgraded by Raymond James with a new price targetRaymond James upgraded Edwards Lifesciences from Mkt Perform to Outperform and set a new price target of $96.00
- Edwards Lifesciences upgraded by Wolfe ResearchWolfe Research upgraded Edwards Lifesciences from Underperform to Peer Perform
- Edwards Lifesciences upgraded by Jefferies with a new price targetJefferies upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $98.00
- Edwards Lifesciences upgraded by Evercore ISI with a new price targetEvercore ISI upgraded Edwards Lifesciences from In-line to Outperform and set a new price target of $88.00
- Edwards Lifesciences upgraded by BTIG Research with a new price targetBTIG Research upgraded Edwards Lifesciences from Neutral to Buy and set a new price target of $100.00
- Edwards Lifesciences upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00
- Edwards Lifesciences upgraded by Stifel with a new price targetStifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously
- Edwards Lifesciences upgraded by BofA SecuritiesBofA Securities upgraded Edwards Lifesciences from Neutral to Buy
- Edwards Lifesciences upgraded by Daiwa SecuritiesDaiwa Securities upgraded Edwards Lifesciences from Neutral to Outperform
- Edwards Lifesciences upgraded by Wolfe ResearchWolfe Research upgraded Edwards Lifesciences from Underperform to Peer Perform
- Edwards Lifesciences upgraded by Citigroup with a new price targetCitigroup upgraded Edwards Lifesciences from Neutral to Buy and set a new price target of $105.00 from $98.00 previously
- Edwards Lifesciences upgraded by Deutsche BankDeutsche Bank upgraded Edwards Lifesciences from Hold to Buy
- Edwards Lifesciences upgraded by BofA SecuritiesBofA Securities upgraded Edwards Lifesciences from Neutral to Buy
- Edwards Lifesciences upgraded by Wells Fargo with a new price targetWells Fargo upgraded Edwards Lifesciences from Equal Weight to Overweight and set a new price target of $94.00
- Edwards Lifesciences upgraded by Oppenheimer with a new price targetOppenheimer upgraded Edwards Lifesciences from Perform to Outperform and set a new price target of $90.00
- Edwards Lifesciences upgraded by Bernstein with a new price targetBernstein upgraded Edwards Lifesciences from Mkt Perform to Outperform and set a new price target of $135.00 from $132.00 previously
- Edwards Lifesciences upgraded by UBS with a new price targetUBS upgraded Edwards Lifesciences from Neutral to Buy and set a new price target of $126.00 from $121.00 previously
- Edwards Lifesciences upgraded by JP Morgan with a new price targetJP Morgan upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $140.00
- Edwards Lifesciences upgraded by Citigroup with a new price targetCitigroup upgraded Edwards Lifesciences from Neutral to Buy and set a new price target of $142.00 from $120.00 previously
- Edwards Lifesciences upgraded by Wells Fargo with a new price targetWells Fargo upgraded Edwards Lifesciences from Equal-Weight to Overweight and set a new price target of $126.00
- Edwards Lifesciences upgraded by Evercore ISIEvercore ISI upgraded Edwards Lifesciences from In-line to Outperform